Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Abstract

Human epidermal growth factor receptor 2-positive breast cancer (HER2+BC) is a common malignancy that is prone to recurrence and metastasis in the early stages, resulting in a poor prognosis for patients. Many studies have suggested that targeted therapy promotes clinical outcomes in HER2+BC. With the introduction of trastuzumab in 1998, the prognosis of patients with early HER2+BC has improved significantly. However, owing to obstinate drug resistance and adverse events, the addition of new agents in standardized treatment has become a research hotspot. These promising agents include antibodies, antibody-drug conjugates, tyrosine kinase inhibitors, and anti-HER2 combined therapies. This article provides a brief description of the biology of BC and the expression of HER2, with the aim to provide an overview of the therapeutic landscape of HER2+BC by reviewing research results and introducing the latest evidence to provide a reference for clinical treatment.

• Authors: Jindong Xie, Yutian Zou, Ting Gao, Liming Xie, Duxun Tan, Xiaoming Xie
• Journal: Cancer control : journal of the Moffitt Cancer Center (Cancer Control) 2022 Jan-Dec Vol. 29 Pg. 10732748221099230 ISSN: 1526-2359 [Electronic] United States
• PMID: 35499382 (Publication Type: Journal Article)

Chemical References

• ERBB2 protein, human
• Receptor, ErbB-2
• Trastuzumab

Topics

• Breast Neoplasms (pathology)
• Female
• Humans
• Molecular Targeted Therapy
• Receptor, ErbB-2 (metabolism)
• Trastuzumab (therapeutic use)